This early-stage trial tests whether adding an experimental treatment (MB097) to the immunotherapy drug pembrolizumab is safe and shows signs of working in people with advanced melanoma that did not respond to standard anti-PD1 therapy. About 41 participants will receive the comb…
Phase: PHASE1 • Sponsor: Microbiotica Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC